WO2007016350A3 - Modified release tablet formulations with enhanced mechanical properties - Google Patents
Modified release tablet formulations with enhanced mechanical properties Download PDFInfo
- Publication number
- WO2007016350A3 WO2007016350A3 PCT/US2006/029427 US2006029427W WO2007016350A3 WO 2007016350 A3 WO2007016350 A3 WO 2007016350A3 US 2006029427 W US2006029427 W US 2006029427W WO 2007016350 A3 WO2007016350 A3 WO 2007016350A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mechanical properties
- modified release
- release tablet
- tablet formulations
- enhanced mechanical
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000007912 modified release tablet Substances 0.000 title 1
- 230000001419 dependent effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 229920003135 Eudragit® L 100-55 Polymers 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A method of formulating a drug in solid dosage form of a specified hardness, the drug containing at least one pharmaceutically active agent that has a pH dependent release profile, at least one non-pH dependent sustained release agent, and an effective amount of Eudragit L100-55.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06788799A EP1909767A2 (en) | 2005-07-28 | 2006-07-28 | Modified release tablet formulations with enhanced mechanical properties |
JP2008524198A JP2009502957A (en) | 2005-07-28 | 2006-07-28 | Sustained release tablet formulation with improved mechanical properties |
CA002616845A CA2616845A1 (en) | 2005-07-28 | 2006-07-28 | Modified release tablet formulations with enhanced mechanical properties |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70300005P | 2005-07-28 | 2005-07-28 | |
US60/703,000 | 2005-07-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007016350A2 WO2007016350A2 (en) | 2007-02-08 |
WO2007016350A3 true WO2007016350A3 (en) | 2007-05-31 |
Family
ID=37692541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/029427 WO2007016350A2 (en) | 2005-07-28 | 2006-07-28 | Modified release tablet formulations with enhanced mechanical properties |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1909767A2 (en) |
JP (1) | JP2009502957A (en) |
CA (1) | CA2616845A1 (en) |
WO (1) | WO2007016350A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009087663A2 (en) * | 2007-11-30 | 2009-07-16 | Sun Pharmaceutical Industries Ltd. | Oral controlled release coated tablet |
SMT201700346T1 (en) | 2008-11-13 | 2017-09-07 | Nogra Pharma Ltd | Antisense compositions and methods of making and using same |
AT10562U3 (en) * | 2008-12-05 | 2010-01-15 | Aop Orphan Pharmaceuticals Ag | A NEW COMPOSITION FOR TREATING AN ESSENCIAL THROMBOCYTEMIA |
RU2734632C2 (en) * | 2010-02-03 | 2020-10-21 | Фарма Ту Б Лтд. | Rasagiline compositions with prolonged release and use thereof |
CN102138906B (en) * | 2011-04-11 | 2012-09-05 | 合肥合源药业有限公司 | Clonidine hydrochloride sustained release micropill preparation |
TW202400130A (en) | 2022-06-15 | 2024-01-01 | 日商澤井製藥股份有限公司 | Guanfacine hydrochloride containing pharmaceutical preparation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020168404A1 (en) * | 1998-07-20 | 2002-11-14 | Isabelle Rault | Use of an acrylic type polymer as disintegrating agent |
US6811794B2 (en) * | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
-
2006
- 2006-07-28 JP JP2008524198A patent/JP2009502957A/en active Pending
- 2006-07-28 EP EP06788799A patent/EP1909767A2/en not_active Withdrawn
- 2006-07-28 CA CA002616845A patent/CA2616845A1/en not_active Abandoned
- 2006-07-28 WO PCT/US2006/029427 patent/WO2007016350A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020168404A1 (en) * | 1998-07-20 | 2002-11-14 | Isabelle Rault | Use of an acrylic type polymer as disintegrating agent |
US6811794B2 (en) * | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
Non-Patent Citations (3)
Title |
---|
OFOEFULE S I ET AL: "USE OF ACRYCLIC AND METACRYLIC ACID DERIVATIVES AS SUSTAINED RELEASE MATRICES FOR THEOPHYLLINE HYDRATE TABLETS", BOLLETTINO CHIMICO FARMACEUTICO, SOCIETA EDITORIALE FARMACEUTICA, MILANO, IT, vol. 138, no. 10, 1999, pages 526 - 530, XP001030890, ISSN: 0006-6648 * |
SCHULZE M D ET AL: "Indices of tableting performance for acrylic resin polymers with plastic and brittle drugs", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY 1993 UNITED STATES, vol. 19, no. 12, 1993, pages 1393 - 1411, XP008077210, ISSN: 0363-9045 * |
TAKKA S ET AL: "INFLUENCE OF METHACRYLIC ACID AND HYDROXYPROPYLMETHYL CELLULOSE ON THE TABLET PROPERTIES AND IN VITRO RELEASE OF DEXTROMETHORPHAN HYDROBROMIDE", PHARMAZIE, DIE, GOVI VERLAG, ESCHBORN, DE, vol. 58, no. 12, December 2003 (2003-12-01), pages 886 - 890, XP001178399, ISSN: 0031-7144 * |
Also Published As
Publication number | Publication date |
---|---|
CA2616845A1 (en) | 2007-02-08 |
WO2007016350A2 (en) | 2007-02-08 |
JP2009502957A (en) | 2009-01-29 |
EP1909767A2 (en) | 2008-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007008752A3 (en) | Sustained release pharmaceutical compositions for highly water soluble drugs | |
WO2011049706A8 (en) | Orally transformable tablets | |
WO2010035273A3 (en) | Novel gastroretentive delivery system | |
TR200200562T2 (en) | Pharmaceutical compositions for oral release that can be secreted in the body in a controlled manner and prevent unpleasant taste | |
WO2007036952A3 (en) | Novel sustained release dosage form | |
PT1827396T (en) | Oral medicament for the modified release of at least one active principle, in multimicrocapsule form | |
WO2007135193A3 (en) | Sustained-release alcohol-resistant multimicroparticulate oral pharmaceutical form comprising anti-misuse means | |
WO2006084164A3 (en) | Gastric retention and controlled release delivery system | |
IL188744A0 (en) | High drug load formulations and dosage forms | |
WO2007050294A3 (en) | Liquid dosage forms having enteric properties of delayed and then sustained release | |
IL191804A0 (en) | Solid dispersion containing an active ingredient and tablets for oral administration containing the same | |
ZA200900929B (en) | Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same | |
WO2009045795A3 (en) | Galenical formulations of aliskiren and valsartan | |
WO2006138048A3 (en) | Formulations comprising fluphenazine or derivatives thereof | |
ATE505203T1 (en) | PHARMACEUTICAL COMBINATION OF ALISKIREN AND VALSARTAN | |
BG108516A (en) | Pharmaceutical formulation | |
WO2007016350A3 (en) | Modified release tablet formulations with enhanced mechanical properties | |
EP1783137A4 (en) | Galactose derivative, drug carrier and medicinal composition | |
WO2008003050A3 (en) | Gallium nitrate formulations | |
WO2005007137A8 (en) | Tablets containing ambroxol | |
WO2010052466A8 (en) | Pharmaceutical aerosol composition | |
WO2008128191A3 (en) | Oral cephalotaxine dosage forms | |
WO2008039351A3 (en) | Method of manufacturing tablets containing pharmacologically active agents | |
WO2011058336A3 (en) | Tablet comprising gum arabic | |
WO2002034240A3 (en) | Delayed and sustained release formulations and method of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2616845 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008524198 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006788799 Country of ref document: EP |